In SURMOUNT-1 (adults with obesity, no diabetes, 72 weeks), tirzepatide produced about 15%, 19.5% and 20.9% mean total body-weight loss at 5, 10 and 15 mg, versus ~3% on placebo. In a head-to-head trial (SURMOUNT-5) it produced more weight loss than semaglutide (~20% vs ~14%). As always, these are averages — individual results vary widely.
(includes the Semaglutide vs Tirzepatide comparison; a standalone /treat/glp1/semaglutide-vs-tirzepatide page can lift that section verbatim for the head-to-head query.)
DRUG FACT PANEL
| Generic | Tirzepatide |
| Brands | Zepbound (weight management; obstructive sleep apnea with obesity), Mounjaro (type 2 diabetes) — SC once-weekly |
| Class | GLP-1 / GIP dual receptor agonist ("twincretin") |
| Mechanism (1 line) | Activates two incretin receptors (GLP-1 and GIP) — reduces appetite, increases satiety, slows gastric emptying, improves glucose |
| FDA indications | Chronic weight management; type 2 diabetes; moderate-to-severe obstructive sleep apnea in adults with obesity |
| Titration concept | Started low, increased stepwise over months to limit GI effects — clinician-set, not from this page |
| Expected effect | ~15–21% mean total weight loss at 72 weeks by dose (SURMOUNT-1); ~20% vs semaglutide's ~14% head-to-head |
| Evidence level (obesity) | Grade A 🟢 |
What tirzepatide is
Tirzepatide is a single molecule that activates two gut-hormone receptors — GLP-1 and GIP — sometimes called a "twincretin" or dual agonist. Like semaglutide, the same molecule carries two brand names: Zepbound for weight management and sleep apnea, Mounjaro for type 2 diabetes. Once-weekly injection. → GLP-1 hub for the incretin biology.
How it works — and what the second hormone adds
The GLP-1 component does what it does with semaglutide: more satiety, less appetite and food noise, slowed gastric emptying, better glucose control. Adding GIP activity appears to further improve appetite regulation and metabolic handling of fat and glucose, and — in head-to-head data — translated into greater average weight loss. The precise mechanism by which GIP agonism helps is still being worked out (GIP biology in obesity is genuinely complex, and both GIP agonism and, paradoxically, antagonism have shown metabolic effects in research). We flag that honestly rather than over-explaining it.
What the trials actually show
Weight (obesity, no diabetes) — SURMOUNT-1, 72 weeks: ~15% / ~19.5% / ~20.9% mean at 5 / 10 / 15 mg vs ~3% placebo; a substantial fraction on 15 mg lost ≥25%.
Weight (type 2 diabetes) — SURMOUNT-2: meaningful loss but, as with all these drugs, less than in people without diabetes — expect smaller numbers if you have diabetes.
Diabetes control — SURPASS program: large A1c reductions, frequently getting many patients to target, with weight loss as a bonus. → Obesity & Diabetes
Head-to-head — SURMOUNT-5, 72 weeks: tirzepatide ~20.2% vs semaglutide ~13.7% mean total weight loss. Tirzepatide produced greater average loss in a direct comparison — the strongest evidence on the "which is better for weight" question.
Sleep apnea — SURMOUNT-OSA: in adults with obesity and moderate-to-severe OSA, tirzepatide substantially reduced the apnea-hypopnea index (event frequency), leading to FDA approval for OSA — a genuine end-organ benefit beyond the scale.
Liver: in MASH trials (e.g., SYNERGY-NASH), tirzepatide improved MASH resolution; it is not currently FDA-approved for MASH (semaglutide is), but the liver data are encouraging. → GLP-1 & Fatty Liver
Body composition — read this carefully
Tirzepatide trials, like other large weight-loss studies, show that total loss includes fat mass and fat-free mass. Two honest points:
- The proportion lost as fat is generally favorable (most of the loss is fat), but any rapid loss reduces lean mass to some degree.
- "Lean mass" on DXA is not "skeletal muscle" or "strength." It includes water and organ tissue. Interpreting a lean-mass drop as "the drug destroyed my muscle" overreads the measurement. Resistance training and adequate protein meaningfully protect muscle and function during treatment. → GLP-1 & Muscle Loss · Exercise & Muscle
Side effects, contraindications, monitoring
Side effects mirror the class: predominantly GI (nausea, diarrhea, constipation, vomiting, reduced appetite), worst during escalation, improving over time. Less common: gallbladder disease, pancreatitis (rare), injection-site reactions, dehydration from severe GI symptoms.
Contraindications/cautions: personal/family history of medullary thyroid carcinoma or MEN2 (boxed warning); history of pancreatitis; significant gastroparesis; pregnancy (avoid; stop when pregnancy is planned/confirmed). Tirzepatide can reduce oral-contraceptive effectiveness around dose initiation/escalation — a backup or non-oral method is advised for the first weeks. → Women's Health & Obesity
Monitoring/perioperative: track response and tolerance; protect muscle (protein + resistance training); follow current anesthesia guidance on holding GLP-1/GIP drugs before surgery given delayed gastric emptying.
Stopping tirzepatide and weight regain
The SURMOUNT-4 withdrawal design tells the story: people who continued tirzepatide maintained and extended their loss, while those switched to placebo regained substantial weight. Same lesson as the rest of the class — this is chronic-disease treatment, and maintenance (including possible lower-dose continuation) should be planned before starting. → Weight Regain & Maintenance
SEMAGLUTIDE vs TIRZEPATIDE (no universal winner)
(This section can stand alone at /treat/glp1/semaglutide-vs-tirzepatide for the head-to-head query.)
| Dimension | Semaglutide (Wegovy/Ozempic) | Tirzepatide (Zepbound/Mounjaro) |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Avg weight loss (obesity) | ~15% (STEP 1, 68 wk) | ~15–21% by dose (SURMOUNT-1, 72 wk) |
| Head-to-head (SURMOUNT-5) | ~13.7% | ~20.2% — greater on average |
| Cardiovascular outcomes | Proven MACE reduction (SELECT) | CV outcome trial (SURPASS-CVOT/SURMOUNT-MMO) maturing; not yet an outcomes claim like SELECT |
| Liver (MASH) | FDA-approved for F2–F3 MASH | Positive trial data; not yet approved |
| Sleep apnea | — | FDA-approved for OSA with obesity |
| Oral option | Yes (oral 25 mg for weight) | No (injectable only) |
| Tolerability | GI effects; broadly similar class profile | GI effects; broadly similar class profile |
| Access/cost | Varies by coverage/supply | Varies by coverage/supply |
How to actually choose (the honest version): if maximum average weight loss is the priority, head-to-head data favor tirzepatide. If proven cardiovascular event reduction matters most (e.g., established heart disease), semaglutide has the outcomes trial. If MASH with fibrosis is the driver, semaglutide is the approved option today. If sleep apnea is central, tirzepatide has the indication. If a needle-free option matters, oral semaglutide exists. Tolerability, comorbidities, pregnancy plans, insurance and supply frequently decide it more than a percentage does. "Better" is patient-specific — this is a conversation, not a leaderboard.
SIGNATURE — "What the evidence says: tirzepatide"
- What we know: Largest average weight loss among approved drugs to date; beat semaglutide head-to-head; approved for OSA; strong diabetes data.
- What we think: GIP co-agonism contributes to efficacy; liver and cardiovascular benefits will likely be formalized as trials report.
- What we don't know: Long-term (decade-plus) outcomes; full CV-outcomes and MASH-approval status; long-term muscle/bone effects; best maintenance dosing.
- What patients should do: Choose between agents on your goals and comorbidities, not the headline percentage; protect muscle; plan maintenance from the start.
Questions patients ask
Is Mounjaro the same as Zepbound?
Same molecule (tirzepatide); Mounjaro is branded for diabetes, Zepbound for weight and sleep apnea. Grade A 🟢
Is tirzepatide better than semaglutide?
On average it produced more weight loss head-to-head, but the best choice depends on your goals — CV outcomes favor semaglutide, MASH is approved for semaglutide, OSA and needle-free vary. Grade A 🟢 (efficacy) / B 🟡 (individual choice)
Does tirzepatide help sleep apnea?
Yes — it's FDA-approved for moderate-to-severe OSA in adults with obesity and reduced apnea events in trials. Grade A 🟢
Will it make me lose muscle?
Rapid loss reduces fat-free mass, but most loss is fat, and DXA "lean mass" isn't the same as strength. Protein and resistance training protect muscle. Grade C 🟠 → GLP-1 & Muscle Loss
Can it treat my fatty liver?
Trial data are promising and it improves MASH, but it isn't FDA-approved for MASH yet — semaglutide currently is. Grade B 🟡 → GLP-1 & Fatty Liver
Will I regain weight if I stop?
Yes, substantially, as with the whole class — the defended set point reasserts. Maintenance should be planned. Grade A 🟢 → Weight Regain
KEEP READING
- Semaglutide — the GLP-1-only comparator, in full.
- GLP-1 Side Effects and GLP-1 & Muscle Loss — the concerns, graded.
- GLP-1 & Fatty Liver — why semaglutide (not tirzepatide) has the MASH approval today.
- Weight Regain & Maintenance — the "forever?" question.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: [date] · References: SURMOUNT-1/2/4/5, SURMOUNT-OSA, SURPASS program, SYNERGY-NASH; FDA prescribing information for Zepbound/Mounjaro. Not individualized medical advice.
